A comparison of bleeding complications post-ablation between warfarin and dabigatran

Journal of Interventional Cardiac Electrophysiology

Volumn 35, Issue 1, 2012, Pages 29-33

  Snipelisky, David ^a   Kauffman, Christine ^a   Prussak, Karin ^a   Johns, Gretchen ^a   Venkatachalam, K ^a   Kusumoto, Fred ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anticoagulation; Atrial fibrillation ablation; Dabigatran; Intraprocedural anticoagulation; Warfarin

Indexed keywords

DABIGATRAN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CATHETER ABLATION; ECCHYMOSIS; FEMALE; HEART ATRIUM ARRHYTHMIA; HEMATOMA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK;

AGED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84866096524     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-012-9708-z     Document Type: Article

References (11)

1. Ma, T., Yan, B., & Lam, Y. (2011). Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. Pharmacology & Therapeutics, 129, 185-194.
2. Dahl, O. (2012). New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. Vascular Health and Risk Management, 8, 45-57.
3. Wallentin, L., Yusuf, S., Ezekowitz, M., Alings, M., Flather, M., Franzosi, M., Pais, P., et al. (2010). Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet, 376, 975-983.
4. Reddy, P., Atay, J., Selbovitz, L., Connors, J., Piazza, G., Block, C., Arpino, P., et al. (2011). Dabigatran: a review of clinical and pharmacoeconomic evidence. Critical Pathways in Cardiology, 10, 117-127.
5. Wann, L., Curtis, A., Ellenbogen, K., Estes, M., Ezekowitz, M., Jackman, W., January, C., et al. (2011). ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 123, 1144-1150.
6. Eikelboom, J., Wallentin, L., Connolly, S., Ezekowitz, M., Healey, J., Oldgren, J., Yang, S., et al. (2011). Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation, 123, 2363-2372.
7. Hohnloser, S., Oldgren, J., Yang, S., Wallentin, L., Ezekowitz, M., Reilly, P., et al. (2012). Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation, 125, 669-676. At: http://circ.ahajournals.org/content/early/2012/01/03/ circulationaha.111.055970. Accessed March 1, 2012.
8. Nagarakanti, R., Ezekowitz, M., Oldgren, J., Yang, S., Chernick, M., Aikens, T., Flaker, G., et al. (2011). Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation, 123, 131-136.
9. Knight, B. (2012). Anticoagulation for atrial fibrillation ablation: what is the optimal strategy? Journal of the American College of Cardiology., 59, 1175-1177.
10. Winkle, R. A., Mead, R. H., Engel, G., Kong, M. H., & Patrawala, R. A. (2012). The use of dabigatran immediately after atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology., 23, 264-268.
11. Lakkireddy, D., Reddy, Y., Di Biase, L., Vanga, S., Santangeli, P., Swarup, V., et al. (2012). Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. Journal of the American College of Cardiology., 59(13), 1168-1174.